Compare GECC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GECC | MDXH |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 68.7M |
| IPO Year | 2016 | 2021 |
| Metric | GECC | MDXH |
|---|---|---|
| Price | $5.23 | $0.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $10.75 | $7.67 |
| AVG Volume (30 Days) | 61.0K | ★ 206.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 22.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.92 | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $12.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $0.40 |
| 52 Week High | $10.88 | $5.33 |
| Indicator | GECC | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 34.24 |
| Support Level | $5.08 | $0.51 |
| Resistance Level | $5.37 | $0.75 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 0.00 | 0.26 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.